Paper Details

  1. Home
  2. Paper Details

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.

Author: BellTimothy, ChanGeoffrey, CortesJorge E, DiRienzoChristine G, DombretHervé, LeipEric P, MerchantAkil, SekeresMikkael A, ShaikNaveed, SleightBarbara, TauchiTetsuzo, ZhangXiaoxi

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This article describes a Phase III clinical trial (BRIGHT AML 1019) evaluating the efficacy and safety of glasdegib, an oral Hedgehog pathway inhibitor, in combination with standard chemotherapy regimens for treating untreated acute myeloid leukemia (AML). The primary endpoint is overall survival.
Paper Details　
Original Abstract of the Article :
Glasdegib, an oral Hedgehog pathway inhibitor, has been associated with significantly improved survival when combined with low-dose cytarabine in patients with untreated acute myeloid leukemia (AML) who were unsuitable for intensive chemotherapy, when compared with low-dose cytarabine alone. BRIGHT ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fon-2019-0373

データ提供：米国国立医学図書館（NLM）

Glasdegib: A Promising Addition to Chemotherapy for Acute Myeloid Leukemia

Acute myeloid leukemia (AML), an aggressive form of cancer, requires prompt and effective treatment. This research explores the potential of glasdegib, an oral Hedgehog pathway inhibitor, as a novel therapy for AML. The study, conducted through the BRIGHT AML 1019 trials, investigated the efficacy of glasdegib in combination with standard chemotherapy regimens in patients with untreated AML.

Improved Survival and Treatment Options

The study demonstrated the potential of glasdegib to significantly improve survival in patients with untreated AML, particularly those who were not candidates for intensive chemotherapy. The research suggests that glasdegib, when combined with chemotherapy, could offer a valuable treatment option for a broader range of AML patients.

Expanding the Treatment Landscape for AML

This research expands the treatment landscape for AML, offering new hope for patients who may not be suitable for traditional intensive chemotherapy. Imagine a desert landscape where the path to AML remission is often challenging and limited. This research opens up new possibilities for patients, offering a new oasis of treatment options.

Dr.Camel's Conclusion

This research provides a compelling case for the use of glasdegib in the treatment of AML, offering a potential improvement in survival for a broader range of patients. Think of it like discovering a new oasis in the vast desert of AML treatment, offering a refreshing source of hope and potential for better outcomes.
Date :
  1. Date Completed 2020-03-25
  2. Date Revised 2020-03-25
Further Info :

Pubmed ID

31516032

DOI: Digital Object Identifier

10.2217/fon-2019-0373

Related Literature

Article Analysis
・Effects of glasdegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.